Scrutinizer Report of the Annual General Meeting of the Company held on 17th September, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Evoq Remedies held its Annual General Meeting on 17th September 2025 via video conferencing. Eleven resolutions were put to vote through remote e-voting. Resolutions 1 to 3 (routine items like adoption of accounts and director appointments) passed comfortably with over 91% support. However, Resolutions 4 to 11 were all declined by shareholders — only 14.10% voted in favour (44,000 shares) versus 85.90% against (268,000 shares). The promoter group's votes of about 27.92 lakh shares on Resolutions 4-11 were declared invalid as they were deemed 'related and interested' in those resolutions. As a result, resolutions 4-11 did not pass.
The defeat of 8 out of 11 resolutions is a notable negative signal for the company. Without promoter support being counted (due to related-party interest), public shareholders overwhelmingly rejected these special business items — likely related-party transactions, capital-raising plans, or management compensation. This reflects shareholder dissent and could create governance concerns, delay planned corporate actions, and weigh on the stock given weak promoter standing with minority investors.